Vesugen 20 mg – 10 vials

Vesugen (also known as KED or T-38) is a synthetic tripeptide research compound with the amino acid sequence Lys-Glu-Asp (lysine–glutamic acid–aspartic acid), developed as a Khavinson-style bioregulator targeting vascular tissues. It functions as an epigenetic regulator that interacts with promoter regions of genes in endothelial and vascular cells, promoting complementary DNA-peptide interactions to normalize protein synthesis, enhance cellular proliferation (e.g., via upregulation of Ki-67), and support endothelial integrity and microcirculatory function. In preclinical models (including tissue cultures from young and aged animals, vascular endothelial cultures, and aging studies), Vesugen stimulates endothelial cell proliferation and repair, preserves vascular wall structure, reduces age-related endothelial dysfunction, limits atherosclerosis progression, improves microcirculation, and exhibits geroprotective and vasoprotective effects against oxidative stress, inflammation, and senescence. It may also influence neurotropic signaling in brain tissue for broader neuroprotective potential. Compared to longer peptides or natural extracts, its ultrashort structure provides high stability, bioavailability, and targeted epigenetic modulation without notable adverse effects. Vesugen is utilized in research to investigate mechanisms of vascular homeostasis, endothelial gene regulation, age-related vascular decline (e.g., immunosenescence in vessels, atherosclerosis), preventive strategies for cardiovascular disorders, microcirculatory optimization, anti-aging interventions in vascularized tissues, and the roles of short peptides in epigenetic control of cellular repair, tissue regeneration, and longevity